Ghassan Qabaja

This inventor holds 7 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 2 EPO patents. Top assignee: Transtech Pharma, Inc.. Active years: 2008-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ghassan Qabaja. Retrieved from https://idiyas.com/inventor/ghassan-qabaja

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 2)

% Patents Active = 85.7

CIPO Patents = 2

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 11.6

ph-index = 4

Forward Citations = 110(Granted Patents)

Location History:

High Point, NC (US) (2010)
Jamestown, NC (US) (2008 - 2015)

Company Filing History:

7 out of 49

Transtech Pharma, Inc.

patents

Years Active: 2008-2015

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9045461 - Phenyl-heteroaryl derivatives and methods of use thereof (2015-06-02),

2. 8741900 - Phenyl-heteroaryl derivatives and methods of use thereof (2014-06-03),

3. 8431575 - Phenyl-heteroaryl derivatives and methods of use thereof (2013-04-30),

4. 7820704 - Substituted heteroaryl derivatives, compositions, and methods of use (2010-10-26),

5. 7737285 - Azole derivatives and fused bicyclic azole derivatives as therapeutic agents (2010-06-15),

6. 7714013 - Azole derivatives and fused bicyclic azole derivatives as therapeutic agents (2010-05-11),

7. 7361678 - Azole derivatives and fused bicyclic azole derivatives as therapeutic agents (2008-04-22),

Title: Innovations of Ghassan Qabaja: Pioneering Research in RAGE-Mediated Diseases

Introduction

Ghassan Qabaja, an accomplished inventor based in Jamestown, NC, has made significant contributions to pharmaceutical research. With a remarkable portfolio of seven patents, he is focusing on developing innovative compounds that hold promise in treating serious medical conditions, particularly those associated with RAGE-mediated diseases.

Latest Patents

Among his latest innovations, Ghassan Qabaja has developed phenyl-heteroaryl derivatives, which are detailed in two patents. These compounds are characterized by their Formula (I) and include pharmaceutically acceptable salts. The principal application for these derivatives lies in their therapeutic potential in managing RAGE-mediated diseases, including Alzheimer's Disease. His inventions not only propose methods for preparing these compounds but also highlight pharmaceutical compositions comprising the derivatives themselves, marking a significant advancement in the field.

Career Highlights

Currently employed at Transtech Pharma, Inc., Ghassan Qabaja has been pivotal in driving research initiatives that align with the company's mission to innovate pharmaceutical solutions. His expertise and dedication to advancing medical treatments underscore his status as a key figure in the industry.

Collaborations

Collaboration plays a crucial role in Ghassan's work, allowing him to leverage the knowledge and skills of his peers. Notable collaborators include Robert Carl Andrews and Anitha Hari, with whom he has shared insights and worked collectively on various projects aimed at enhancing drug development and therapeutic applications.

Conclusion

Ghassan Qabaja's contributions to the field of pharmaceuticals through his inventions play a critical role in addressing complex medical challenges. With his ongoing research and collaboration with experts, he is poised to continue making strides in the treatment of RAGE-mediated diseases, benefitting patients and the broader medical community.

Profile summary based on public USPTO records.